Glucose-dependent insulinotropic polypeptide: blood glucose stabilizing effects in patients with type 2 diabetes

What Was Tested

The paper reports a study of GIP (Gastric Inhibitory Polypeptide), published as a randomized controlled trial.

The researchers aimed to evaluate the importance of the prevailing plasma glucose levels for the effect of GIP on responses of glucagon and insulin and glucose disposal in patients with T2DM.

Why It Was Studied

Patients with type 2 diabetes mellitus (T2DM) have clinically relevant disturbances in the effects of the hormone glucose-dependent insulinotropic polypeptide (GIP).

Who Took Part

PubMed indexes the participants as middle-aged adults, men only.

The researchers performed a single center, placebo-controlled, cross-over, experimental study.

How the Study Was Run

The researchers set it up as a randomized, placebo-controlled and crossover study.

Random assignment meant chance, not the researchers, decided who got GIP (Gastric Inhibitory Polypeptide) and who got the comparison, which limits bias.

Some participants received a placebo instead of GIP (Gastric Inhibitory Polypeptide), giving a reference point.

Each person switched between GIP (Gastric Inhibitory Polypeptide) and the comparison at some point, usually with a gap in between.

What Was Measured

Topics PubMed links to this paper include Blood Glucose, Diabetes Mellitus, Type 2, Fasting, Gastric Inhibitory Polypeptide, Glucagon, Hyperglycemia and Hypoglycemia.

What This Means in Plain Language

The paper is a randomized, placebo-controlled and crossover study of GIP (Gastric Inhibitory Polypeptide).

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2014 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the GIP (Gastric Inhibitory Polypeptide) compound page, all human trials.